The company has initiated the first-in-human trial of MVA-BN WEV, a prophylactic vaccine candidate against the equine encephalitis virus – a rare, but potentially deadly illness.
The program, which is funded by the United States Department of Defense (DOD) Joint Project Manager for Chemical, Biological, Radiation, and Nuclear Medical (JPM CBRN Medical) is a multi-year agreement valued up to USD 36 million and aims to develop a vaccine against three separate strains of the equine encephalitis virus, Eastern (EEEV), Venezuelan (VEEV), and Western (WEEV), for which there are currently no preventative vaccines available.
Results expected 2020
The Phase 1 trial will evaluate the safety, tolerability and immunogenicity of MVA-BN WEV in 45 healthy adults in three treatment groups receiving different doses of the vaccine. Topline results from the study are expected to become available in 2020.
A successful Phase 1, based on demonstrating a favorable safety and immunogenicity could lead to follow-on funding, beyond the initial contract award of USD 36 million, to support further preclinical, clinical development and manufacturing to support licensure in the U.S.
“The importance of a vaccine to help fight these diseases”
“After the recent FDA approval of our smallpox vaccine, which was developed in collaboration with various U.S. government agencies and has become an integral part of the national stockpile, we are excited to advance this new program, helping to fulfil the U.S. government’s goal to develop a broad range of medical countermeasures to protect U.S. citizens,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. “The prevalence of Eastern equine encephalitis, which is currently on the rise in the U.S., highlights the importance of a vaccine to help fight these diseases. Again, we are leveraging the unique properties of our MVA-BN platform technology to address unmet medical needs, and we look forward to continuing our work with DOD on this important program.”
Photo of Paul Chaplin: Bavarian Nordic
